Inhibitors of angiogenesis

Clinical and Translational Oncology

Volumn 8, Issue 7, 2006, Pages 475-481

  Almendro, Vanessa ^a   Gascón, Pere ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Angiogenesis; Antiangiogenesis; Inhibitors

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ACTIVID; AGO 15676; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; AVE 8062A; AZP 2171; BAY 459006; BEVACIZUMAB; CILENGITIDE; COMBRETASTATIN; EMD 1294; LENALIDOMIDE; MONOCLONAL ANTIBODY IMC 1C11; MONOCLONAL ANTIBODY LM 609; N ACETYLCOLCHINOL PHOSPHATE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PLACEBO; SEMAXANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; VATALANIB; ZK 22854;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ATAXIA; BACKACHE; BLEEDING; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; COLITIS; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DIVERTICULITIS; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; EDEMA; FATIGUE; HAIR LOSS; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CANCER; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MUCOSAL BLEEDING; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEOVASCULARIZATION (PATHOLOGY); NEUROTOXICITY; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PROSTATE CANCER; PROTEINURIA; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN BLEEDING; STOMACH ULCER; SURVIVAL TIME; THORAX PAIN; THROMBOEMBOLISM; THROMBOSIS; TUMOR BLOOD FLOW; VENOUS THROMBOEMBOLISM; VERTIGO; ANIMAL; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS; HUMANS;

EID: 33748861303     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0047-3     Document Type: Article

References (21)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 1971;285:1182-6.
2. Gullino PM. Angiogenesis and oncogenesis. J Natl Cancer Inst. 1978;61:639-45.
3. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascitis fluid. Science. 1983;219:983-5.
4. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-8.
5. Gerber HP, McMurtrey A, Kowalski J, et al. VEGF regulates endothelial cell survival by the P13-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998;273: 30336-43.
6. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature bloos vessels in established human tumors follows vascular endothelial growth factor with-drawl. J Clin Invest. 1999;105:159-65.
7. Jain RK. Normalizing tumor vasculature with antiangio genic therapy: A new paradigm for combination therapy. Nature Med. 2001;7:987-9.
8. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 2004;10:145-7.
9. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II. Randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-5.
10. Kabbinavar F, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol. 2005;23:3697-705.
11. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23:3502-8.
12. Kabbinavar F, Hambleton J, Mass RD, et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706-12.
13. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab with irinotecan, fluorouracil and leucovorin in the treatment of metastatic colorectal cancer. N Engl J Med. 2004;550:2335-42.
14. Giantonio BJ, Catalana PJ, Meropol NJ, et al. High dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol. 2005;25:16S, abstract #2.
15. Hochster H, et al. Gastointestinal Cancers Symposium, Hollywood, Florida, 2005.
16. Holash J, David S, Papadopoulos N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99:11593-8.
17. Morgan JA, Garrett HJ, Schutte H, et al. Sunitinib for patients (pts) with advanced imatinib (IM)-refractory GIST: Early results from a *treatment-use* trial. Proceedings ASCO. 2006;24:529s, abstract #9540.
18. Rini BI, George DJ, Michaelson JE, et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). Proceedings ASCO. 2006;24:222s, abstract #4522.
19. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the multikinase inhibitor sorafenib (BAY 43-9006) in patients with advanced RCC. European Cancer Conference, ECCO-15. 2005; Personal communication.
20. Gore ME, Scudier B. Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma. Oncology. 2006;20(6 Suppl 5):S19-24.
21. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-71.